Ganirelix acetate (Antagon)

Ganirelix acetate (Antagon) (CAS No.: 123246-29-7) is a synthetic decapeptide classified as a gonadotropin releasing hormone receptor antagonist and is broadly used as a mechanistic research tool in reproductive endocrinology and translational drug discovery programs focused on hypothalamic pituitary gonadal axis regulation, where it functions by competitively binding the GnRH receptor and suppressing downstream G protein coupled signaling that normally drives gonadotropin synthesis and release, thereby enabling controlled interrogation of luteinizing hormone and follicle stimulating hormone dependent cellular responses in endocrine cell systems and related experimental models. In biomedical research contexts, this molecule is commonly positioned within peptide antagonist libraries for target validation, pathway deconvolution, and comparative pharmacology against other neuroendocrine modulators, and available characterization across the GnRH antagonist class indicates potent receptor level activity generally observed in the nanomolar range, while broader phenotypic effects in complex in vitro systems may extend into higher concentration windows depending on receptor density, assay design, and exposure time. Typical use cases include receptor signaling assays, hormone secretion studies, ovarian and pituitary axis modeling, and preclinical screening workflows in which concentrations or doses used in experiments typically depend on specific experimental designs and research objectives, with endpoint selection often centered on receptor occupancy related signaling changes, transcriptional regulation of gonadotropin associated genes, and time dependent endocrine feedback dynamics in cell based platforms and animal research models.